LU84346A1 - Nouveau sel de n-methyl-d-glucamine et medicament le contenant - Google Patents
Nouveau sel de n-methyl-d-glucamine et medicament le contenant Download PDFInfo
- Publication number
- LU84346A1 LU84346A1 LU84346A LU84346A LU84346A1 LU 84346 A1 LU84346 A1 LU 84346A1 LU 84346 A LU84346 A LU 84346A LU 84346 A LU84346 A LU 84346A LU 84346 A1 LU84346 A1 LU 84346A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- methyl
- salt
- solution
- glucamine
- acid
- Prior art date
Links
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title claims description 12
- 150000003839 salts Chemical class 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 11
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000008366 buffered solution Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 231100000344 non-irritating Toxicity 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- WIZAMTSKPRSWIL-UHFFFAOYSA-N tiprinast Chemical compound N1=C(C(O)=O)NC(=O)C2=C1SC(CC(C)C)=C2C WIZAMTSKPRSWIL-UHFFFAOYSA-N 0.000 claims 1
- 229940100613 topical solution Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- -1 alkali metal salts Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical class CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical class OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052700 potassium Chemical class 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/294,962 US4377583A (en) | 1981-08-21 | 1981-08-21 | N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid |
| US29496281 | 1981-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU84346A1 true LU84346A1 (fr) | 1983-06-07 |
Family
ID=23135663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU84346A LU84346A1 (fr) | 1981-08-21 | 1982-08-20 | Nouveau sel de n-methyl-d-glucamine et medicament le contenant |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4377583A (de) |
| JP (1) | JPS5843976A (de) |
| KR (1) | KR870001240B1 (de) |
| AT (1) | AT381314B (de) |
| AU (1) | AU558004B2 (de) |
| BE (1) | BE894162A (de) |
| CA (1) | CA1224465A (de) |
| CH (1) | CH651569A5 (de) |
| DE (1) | DE3231103A1 (de) |
| DK (1) | DK164059C (de) |
| ES (1) | ES515156A0 (de) |
| FI (1) | FI74965C (de) |
| FR (1) | FR2511680B1 (de) |
| GB (1) | GB2104521B (de) |
| GR (1) | GR76250B (de) |
| IE (1) | IE53804B1 (de) |
| IT (1) | IT1149064B (de) |
| LU (1) | LU84346A1 (de) |
| MY (1) | MY8800122A (de) |
| NL (1) | NL8203280A (de) |
| PT (1) | PT75446A (de) |
| SE (1) | SE453504B (de) |
| ZA (1) | ZA826019B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753701A (en) * | 1996-10-25 | 1998-05-19 | University Of Kentucky | N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters as novel safe agents for water disinfection |
| US20050239748A1 (en) * | 2004-03-17 | 2005-10-27 | Panacos Pharmaceuticals, Inc. | Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| US11571431B2 (en) * | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| EP3781155A4 (de) * | 2018-04-17 | 2021-10-06 | Cardurion Pharmaceuticals, LLC | Megluminsalze von thienopyrimidinen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4054656A (en) * | 1975-09-10 | 1977-10-18 | Mead Johnson & Company | Thieno[2,3-d]pyrimidine antiallergic agents |
-
1981
- 1981-08-21 US US06/294,962 patent/US4377583A/en not_active Expired - Fee Related
-
1982
- 1982-08-12 GR GR69028A patent/GR76250B/el unknown
- 1982-08-18 ZA ZA826019A patent/ZA826019B/xx unknown
- 1982-08-18 JP JP57142228A patent/JPS5843976A/ja active Granted
- 1982-08-19 DK DK372282A patent/DK164059C/da not_active IP Right Cessation
- 1982-08-19 IT IT49006/82A patent/IT1149064B/it active
- 1982-08-19 PT PT75446A patent/PT75446A/pt not_active IP Right Cessation
- 1982-08-19 AU AU87430/82A patent/AU558004B2/en not_active Ceased
- 1982-08-19 CA CA000409740A patent/CA1224465A/en not_active Expired
- 1982-08-20 ES ES515156A patent/ES515156A0/es active Granted
- 1982-08-20 LU LU84346A patent/LU84346A1/fr unknown
- 1982-08-20 SE SE8204792A patent/SE453504B/sv not_active IP Right Cessation
- 1982-08-20 FI FI822907A patent/FI74965C/fi not_active IP Right Cessation
- 1982-08-20 IE IE2017/82A patent/IE53804B1/en not_active IP Right Cessation
- 1982-08-20 BE BE0/208853A patent/BE894162A/fr not_active IP Right Cessation
- 1982-08-20 KR KR8203744A patent/KR870001240B1/ko not_active IP Right Cessation
- 1982-08-20 FR FR8214406A patent/FR2511680B1/fr not_active Expired
- 1982-08-20 DE DE19823231103 patent/DE3231103A1/de active Granted
- 1982-08-20 GB GB08224025A patent/GB2104521B/en not_active Expired
- 1982-08-20 NL NL8203280A patent/NL8203280A/nl not_active Application Discontinuation
- 1982-08-23 AT AT0318382A patent/AT381314B/de not_active IP Right Cessation
- 1982-08-23 CH CH5001/82A patent/CH651569A5/de not_active IP Right Cessation
-
1988
- 1988-12-30 MY MY122/88A patent/MY8800122A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0165919B1 (de) | (R)-Alpha-ethyl-2-oxo-1-pyrrolidinacetamid | |
| EP0755398B1 (de) | Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten | |
| CH625511A5 (en) | Process for the preparation of new hydantoin derivatives | |
| EP0138721A2 (de) | Benzensulfonyllactame, Verfahren zu ihrer Herstellung und ihre Anwendung als wirksame Bestandteile in pharmazeutischen Zusammensetzungen | |
| DE1795022C3 (de) | Lysergsäurederivate | |
| GB2038818A (en) | ???,???-Dihydropolyprenyl Alcohols and Pharmaceutical Compositions thereof | |
| LU84346A1 (fr) | Nouveau sel de n-methyl-d-glucamine et medicament le contenant | |
| LU87774A1 (fr) | (2r,cis)-1,2-epoxypropyl-phosphonate de mono-(2-ammonium-2-hydroxymethyl 1,3-propanediol)ayant des caracteristiques ameliorees de stabilite,son procede de preparation et compositions pharmaceutiques le contenant | |
| HRP20090470A2 (hr) | Sol 3-benzil-2-methil-2.3.3.a.4.5.6.7,7a-octahidrobenzo[d]isoksazol-4-ona | |
| FR2467848A1 (fr) | Sels d'acides 6,7-dihalo-3,4-dihydro-3-oxo-2-quinoxalinecarboxyliques et d'amines steriquement encombrees, leur preparation et leur utilisation therapeutique | |
| FR2570701A1 (fr) | Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique | |
| FR2459658A1 (fr) | Procede de preparation d'une composition pharmaceutique a base de methoxsalen administrable par voie orale | |
| US3839317A (en) | Digoxin complexes | |
| FR2476095A1 (en) | Glyceryl 2-para-chloro:phenoxy-isobutyrate-1,3-di:nicotinate - hypolipaemic and hypocholesterolaemic used to treat atherosclerosis, hyperlipoproteinaemia and high tri:glyceride plasma levels | |
| FR2481283A1 (de) | ||
| CH615673A5 (de) | ||
| FR2566775A1 (fr) | Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique | |
| KR950008316B1 (ko) | 1-히드록시-5-옥소-5H-피리도[3,2-a]페녹사진-3-카르복실산 에스테르 | |
| LU82965A1 (fr) | Nouveaux sels d'addition d'acides du 4'-(9-acridinylamino)methanesulf-m-anisidide,leur procede de production et composition pharmaceutique les contenant | |
| EP0078518B1 (de) | p-Chlorophenoxyessigsäure-Derivat, Verfahren zu dessen Herstellung und pharmazeutische Zusammenstellung | |
| EP0449722B1 (de) | Neue Komplexe der Tiaprofensäure oder ihrer unlöslichen oder zum Teil löslichen Ester mit den Cyclodextrinen oder ihren Derivaten | |
| EP0082040A1 (de) | 3,7a-Diazacyclohepta(j,k)fluorenderivate, ihre Herstellung und ihre therapeutische Verwendung | |
| FR2507892A1 (fr) | Compositions antibronchospastiques contenant un sel de theophylline avec un acide amine et leur preparation | |
| EP1779852A2 (de) | Verfahren zur Herstellung von Sildenafil-Base und Zitratsalz | |
| FR2461725A1 (en) | Mono and bis di:isopropylamine serine-phosphate(s) - are peripheral vasodilators and antiparkinson agents |